Osteoarthritis: ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• GLP-1 2
• MAPK 0
• PI3K 0
• AKT 0
• IL-6 0
• mTOR 0
• NLRP3 0
• STAT3 0
• AMPK 0
• JAK 0
• NRF2 0
• COX-2 0
• SIRT1 0
• STING 0
• TNF 0
• VEGF 0
• CGRP 0
• ERK 0
• FTO 0
• HIF-1 0
• IL-1 0
• RANKL 0
• SGLT2 0
• TP53 0
• APP 0
• CDK4/6 0
• CFTR 0
• CTNNB1 0
• EGFR 0
• GIP 0
• HER2 0
• IL-15 0
• JNK 0
• METTL3 0
• MMP-9 0
• PINK1 0
• PPAR 0
• TLR4 0
• YAP 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC

  Biofabrication of gene activated grafts targeting synovial joint inflammation and meniscus repair (SMART-MENISCUS)

  The Provost, Fellows, Foundation Scholars & the Other Members of Board, of the College of the Holy & Undivided Trinity of Queen Elizabeth Near Dublin· Dublin, Írország· EU contribution 1 500 000 EUR· until 2032. jan.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  EV-enriched secretome from cord blood as a new disease modifying treatment for osteoarthritis (ExoCordOA)

  Exogenus Therapeutics Sa· Cantanhede, Portugália· EU contribution 13 000 000 EUR· until 2031. aug.· 3 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Smart Platforms for Osteochondral Regeneration through on-demand Activation (SPORA)

  Instituto Superior Tecnico· Lisboa, Portugália· EU contribution 191 343 EUR· until 2028. aug.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Newly engineered lignin nanocarrier for curcumin delivery to tackle inflammation and limited synovial drug residence in osteoarthritis (LigNPsCURCDeLIV)

  University of Leeds· Leeds, Egyesült Királyság· EU contribution 276 188 EUR· until 2028. szept.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Gene-activated tri-layer 3D-bioprinted scaffold for enhanced osteochondral defect repair (GATSO-3D)

  Royal College of Surgeons in Ireland· Dublin 2, Írország· EU contribution 252 729 EUR· until 2028. júl.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  SakuraBead - pain agnostic treatment for everyone

  Crannmed Ltd· Galway, Írország· EU contribution 2 366 802 EUR· until 2028. máj.

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  Patient Relevant Osteoarthritis endpoints using Big data Evaluation (PROBE)

  Erasmus Universitair Medisch Centrum Rotterdam· Rotterdam, Hollandia· EU contribution 13 999 883 EUR· until 2030. nov.· 16 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Regenerative engineering innovation in early intervention of osteoarthritis (RENOVATE)

  Universidad de Las Palmas de Gran Canaria· Las Palmas De Gran Canaria, Spanyolország· EU contribution 2 881 647 EUR· until 2029. okt.· 6 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Connecting Joint Function to Chondrocyte Biology in Knee Osteoarthritis (OA-CONNECT)

  Katholieke Universiteit Leuven· Leuven, Belgium· EU contribution 3 283 437 EUR· until 2030. szept.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Social PrEscribing integration in the Care Pathway for people with OsteoArthritis - SPECs-OA (SPECS-OA)

  Royal College of Surgeons in Ireland· Dublin 2, Írország· EU contribution 252 729 EUR· until 2027. aug.

10 of 25 running projects, newest first. Listed amounts together: 106,0 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 43
• Organoids 4
• Mendelian Randomization Analysis 55
• CRISPR-Cas Systems 1
• Gene Expression Profiling 106
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 3
• Exome Sequencing 1
• Proteomics 43
• Metabolomics 26
• Mass Spectrometry 5
• Flow Cytometry 7
• Immunohistochemistry 19
• Positron-Emission Tomography 6
• Magnetic Resonance Imaging 276
• Machine Learning 78
• Deep Learning 45
• Cohort Studies 148
• Genome-Wide Association Study 48

• Mapping articular cartilage maturation across postnatal development by proteomics.

  Osteoarthritis Cartilage, 2026. jún.

• Mass Spectrometry-Based Screening Reveals Inhibitors of Cholesterol 25-Hydroxylase.

  ACS Chem Biol, 2026. jún.

• Tissue and extracellular matrix remodeling of the subchondral bone during osteoarthritis of knee joints as revealed by spatial mass spectrometry imaging.

  Bone Res, 2026. jan.

• Rapid Detection of Adulteration in Boswellia Extracts with Citric Acid by UPLC-HRMS and 1H NMR.

  J Diet Suppl, 2024. jan.

• Plasma and joint tissue pharmacokinetics of two doses of oral cannabidiol oil in guinea pigs (Cavia porcellus).

  J Vet Pharmacol Ther, 2021. okt.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.